These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 31739402)
1. Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity. Azambuja JH; Ludwig N; Braganhol E; Whiteside TL Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739402 [TBL] [Abstract][Full Text] [Related]
2. Targeting adenosine in cancer immunotherapy: a review of recent progress. Whiteside TL Expert Rev Anticancer Ther; 2017 Jun; 17(6):527-535. PubMed ID: 28399672 [TBL] [Abstract][Full Text] [Related]
3. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G Front Immunol; 2019; 10():925. PubMed ID: 31244820 [TBL] [Abstract][Full Text] [Related]
4. Targeting adenosinergic pathway and adenosine A Abouelkhair MA Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324 [TBL] [Abstract][Full Text] [Related]
5. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment. Xing J; Zhang J; Wang J Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834375 [TBL] [Abstract][Full Text] [Related]
6. Adenosine signaling and the immune system: When a lot could be too much. Antonioli L; Fornai M; Blandizzi C; Pacher P; Haskó G Immunol Lett; 2019 Jan; 205():9-15. PubMed ID: 29702147 [TBL] [Abstract][Full Text] [Related]
8. Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy. Yang H; Zhang Z; Zhao K; Zhang Y; Yin X; Zhu G; Wang Z; Yan X; Li X; He T; Wang K Hum Immunol; 2024 May; 85(3):110774. PubMed ID: 38521664 [TBL] [Abstract][Full Text] [Related]
9. Canonical and non-canonical adenosinergic pathways. Ferretti E; Horenstein AL; Canzonetta C; Costa F; Morandi F Immunol Lett; 2019 Jan; 205():25-30. PubMed ID: 29550257 [TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory activity of adenosine and its role in human cancer progression. Muller-Haegele S; Muller L; Whiteside TL Expert Rev Clin Immunol; 2014 Jul; 10(7):897-914. PubMed ID: 24871693 [TBL] [Abstract][Full Text] [Related]
11. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. Bao X; Xie L J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249 [TBL] [Abstract][Full Text] [Related]
12. The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy. Kang C; Liu L; Wu C; Li L; Jia X; Xie W; Chen S; Wu X; Zheng H; Liu J; Li R; Zeng B Front Immunol; 2023; 14():1111369. PubMed ID: 36911717 [TBL] [Abstract][Full Text] [Related]
13. Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment. Chiarella AM; Ryu YK; Manji GA; Rustgi AK Trends Cancer; 2021 Aug; 7(8):731-750. PubMed ID: 34074623 [TBL] [Abstract][Full Text] [Related]
14. Adenosinergic signaling as a target for natural killer cell immunotherapy. Wang J; Matosevic S J Mol Med (Berl); 2018 Sep; 96(9):903-913. PubMed ID: 30069747 [TBL] [Abstract][Full Text] [Related]
15. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration. Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090 [TBL] [Abstract][Full Text] [Related]
18. Extracellular ATP and adenosine: The Yin and Yang in immune responses? Faas MM; Sáez T; de Vos P Mol Aspects Med; 2017 Jun; 55():9-19. PubMed ID: 28093236 [TBL] [Abstract][Full Text] [Related]